| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.33 | 7e-16 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.35 | 3e-06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 5e-05 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0005 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |